Affordable & Accessible for All

5 August 2026

Cancer treatment can be life-changing for patients, but it can also place a substantial financial burden on healthcare systems, patients and families. As cancer incidence continues to rise globally, developing treatments that are not only effective but also scalable, accessible and affordable will become increasingly important.

At OncoLize, affordability and accessibility are part of the way we think about innovation from the start.

The goal is not simply to develop a new cancer treatment technology. It is to develop a platform that could ultimately be produced, administered and scaled in healthcare settings around the world.

Starting with established oncology drugs

One part of the OncoLize approach is to work with well-established oncology drugs.

Many chemotherapy drugs have been used in clinical practice for years and are widely available. Most are also off-patent and relatively affordable compared with many newer therapies.

Instead of developing an entirely new active pharmaceutical ingredient for every application, the ChemoGell™ platform is designed to explore whether established drugs can be delivered in a different and potentially more localized way.

This approach could offer several practical advantages, including access to existing drug supply chains and established knowledge about the properties and use of these compounds. The approach to use well-established drugs simplifies the approval pathway and short-cuts the costly safety studies required with novel drug candidates, and which often fail in development because of the unexpected side-effects in ineffectiveness of these novel drug candidates.

A platform designed for practical administration

A technology can only become widely useful if it can be incorporated into real-world clinical practice.

ChemoGell™ is designed as an injectable hydrogel platform that can be delivered using established medical techniques. Depending on the tumor and clinical situation, the formulation can be administered through a thin needle, catheter or endoscope.

This means the technology is intended to work with medical tools that clinicians already use rather than requiring an entirely new treatment infrastructure. In fact, many of the procedures and the infra-structure are well-established in the way biopsies are taken of the tumor lesions to begin with.

The ChemoGell™ depot is also imageable using CT and ultrasound. This will support image-guided placement and monitoring of the localized drug depot, including procedures involving difficult-to-reach solid tumors.

Scalable manufacturing

Affordability is also closely connected to how a treatment is manufactured.

The ChemoGell™ platform uses bio-erodible, pharmaceutical-grade polymers and an aqueous formulation process. The basic manufacturing approach involves standard mixing and compounding of the drug and excipients.

This is important because manufacturing does not necessarily require highly specialized facilities built exclusively for the ChemoGell™ platform.

OncoLize's formulations could potentially be produced by specialized contract manufacturers or, where appropriate and permitted, by hospital pharmacies with the capacity to process sterile injectable products and chemo-toxins.

This could create flexibility in how products are manufactured and supplied as the technology develops, or even allow for patient-specific formulations.

Accessible ingredients and established processes

The platform is designed around materials and processes that can support practical scale-up.

The polymers used by OncoLize are pharmaceutical-grade and commercially available. Combined with established oncology drugs and standard formulation processes, this creates a foundation for developing products without relying entirely on rare or highly specialized raw materials and special-made manufacturing equipment.

Of course, achieving commercial affordability involves much more than the cost of raw materials. Regulatory requirements, quality control, clinical development, manufacturing validation, distribution and healthcare delivery all contribute to the final cost of a medicine.

Nevertheless, considering these factors early in the development process can help create a more scalable product strategy.

Why affordability matters in cancer care

The cost of cancer care is a growing concern around the world.

Healthcare systems are under pressure to provide increasingly sophisticated treatments while managing limited resources. At the same time, patients and families can face substantial direct and indirect costs associated with diagnosis and treatment.

Innovation therefore needs to consider more than clinical effectiveness alone.

A treatment that works but cannot be produced at scale or accessed by the patients who need it will have limited impact.

For OncoLize, the ambition is to combine therapeutic innovation with a practical approach to manufacturing and delivery.

From local treatment to global potential

Localized drug delivery may also offer opportunities beyond the initial development of a single product.

The ChemoGell™ platform is being developed as a technology platform rather than a single drug. It has been investigated with different oncology drugs and is intended for potential application across different solid tumor indications.

This platform approach could allow OncoLize and its partners to explore multiple Product-Market Combinations using the same underlying delivery technology.

In the longer term, technology licensing and partnerships could support development in additional markets and tumor types.

Accessibility starts with design

Making cancer treatment more accessible cannot be solved at the end of the development process. It needs to be considered from the beginning.

That means thinking about the drugs used, the materials required, how the formulation is manufactured, what equipment clinicians need, and how the treatment can be delivered in different healthcare environments.

This is the philosophy behind OncoLize's ambition to develop cancer therapies that are not only potentially more effective at the tumor site, but also practical to manufacture and administer.

A simple ambition

OncoLize's vision can be summarized in three words: Effective, Accessible. Affordable.

By combining established oncology drugs with a localized drug-delivery platform, standard clinical tools, scalable formulation processes and potentially flexible manufacturing options, OncoLize aims to create a foundation for cancer treatments that could reach patients in different healthcare systems around the world.

The technology is still under development, and significant clinical, regulatory and manufacturing milestones remain ahead.

But the ambition is clear: innovation in cancer treatment should not only push the boundaries of what is medically possible. It should also consider how those innovations can ultimately reach the people who need them.

Learn more about OncoLize and explore the opportunity to become part of this journey at our investors page.